Zasocitinib, a tyrosine kinase 2 (TYK2) inhibitor, holds promise as a new oral treatment for psoriasis, randomized clinical trial data suggest. Results of the multisite phase 2b trial, which appeared in , presented data from 259 patients with moderate-to-severe plaque psoriasis who were randomized to receive zasocitinib at different dosage levels or placebo.
Antistreptococcal treatments could have therapeutic potential for psoriasis, but their efficacy is uncertain because of limited evidence, according to a recent literature review. Tonsillectomy, however,…
TikTok points researcher toward signal of benefit
These findings must be weighed against the drug’s established efficacy in this disease
Physician-chain joint ownership has also increased, raising eyebrows
When it comes to small cell lung cancer (SCLC), there are a lot of highs and lows. For instance, it has a fairly low incidence…
This elevates a long-standing anti-vaccine conspiracy theory
Kids with addictive use of cell phones, social media, video games have worse mental health
Study also shows 1.3 million would forego their medications after losing coverage
Researchers urge greater attention to ‘cold drink heart’
Real-world reports since 2016 analyzed in updated meta-analysis
